Sygnature Discovery has considerable drug discovery experience across a wide range of therapeutic areas and biological targets. We undertake intelligent integrated drug discovery to deliver small molecules with the potential to be advanced from the discovery phase into pre-clinical development, and beyond into the clinic. Key area of expertise include oncology, respiratory and metabolic disease and CNS disorders.
Sygnature performs integrated drug discovery projects through a unique and synergistic combination of in-house resource and expertise, and a federation of centres of drug discovery expertise located around the world.
We work with our clients in a flexible and collaborative way and can adapt the resource allocated to a drug discovery project to meet each client’s specific requirements and budget. In addition to integrated drug discovery projects we also undertake projects involving purely medicinal chemistry, computational chemistry, in vitro bioscience or DMPK.